News
Sarepta rebuffed a call from the Food and Drug Administration to halt all shipments of its gene therapy for Duchenne muscular ...
As mothers of children with this disease, we have wept helplessly in recent months as friends — fellow members of a club we ...
Shares of Sarepta Therapeutics plunged more than 30% on Friday as the future of its approved gene therapy appeared at risk.
Duchenne Muscular Dystrophy affects 12,000 to 15,000 children and young adults in the United States and about 300,000 worldwide. It's caused by a mutation in the dystrophin gene, which makes a ...
The first patient has been dosed in a clinical trial testing Sardocor's one-time gene therapy for cardiomyopathy associated ...
Following the death of two teenage patients with Duchenne muscular dystrophy following Elevidys treatment, Sarepta ...
Sarepta Therapeutics announced it has laid off more than one-third of its workforce, a drastic cost-cutting move following ...
5d
News-Medical.Net on MSNNew cellular entry pathway improves gene therapy outcomesScientists from the Centenary Institute and the University of Sydney have made a landmark discovery that could lead to safer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results